Treeway’s position in ALS therapy development
Treeway is a clinical-stage biotechnology company with a mission to develop therapies to cure ALS. It was founded in 2012 by two ALS patients, Bernard Muller and Robbert Jan Stuit. Treeway aims to develop drugs that first delay disease progression, followed by therapies that halt or control the disease finally leading to a breakthrough therapy to cure ALS. Currently, Treeway has established a pipeline consisting of two drug therapies, TW001 and TW002, which are in development and is assessing several research lines to validate drugable targets.
In its mission to identify compounds and develop therapies that have the potential to fully halt disease progression, Treeway closely collaborates with (global) research and clinical institutes, and is involved in establishing the grounds for TRICALS, a European institute for performing clinical trials specifically in ALS. Treeway’s founders also initiated Project MinE, the world’s largest-scale research initiative devoted to discovering the genetic cause of ALS. Although Treeway is a young biotech company, it has established relationships with ALS researchers and doctors globally. In addition, Treeway has realized a strong patient empowerment within the target market, which makes Treeway a leader within this therapeutic area.